Sarepta

Business

Citi starts Sarepta at buy, likes risk/reward for DMD drug approval (NASDAQ:SRPT)

phive2015 Citi started coverage of Sarepta Therapeutics (NASDAQ:SRPT) with a buy rating, stating that it likes the risk/reward heading into…

Read More »
Back to top button